Allogene Therapeutics, Inc. (ALLO)
2.33
+0.12
(+5.43%)
USD |
NASDAQ |
Mar 25, 16:00
2.29
-0.04
(-1.72%)
Pre-Market: 09:27
Allogene Therapeutics Cash from Investing (Quarterly) : 33.61M for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | -1.403M |
| Inovio Pharmaceuticals, Inc. | -0.0582M |
| Vaxart, Inc. | 1.989M |
| Capricor Therapeutics, Inc. | 43.09M |
| Agenus, Inc. | 0.78M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -27.60M |
| Cash from Financing (Quarterly) | 7.859M |
| Free Cash Flow | -149.63M |
| Free Cash Flow Per Share (Quarterly) | -0.1221 |
| Free Cash Flow to Equity (Quarterly) | -25.71M |
| Free Cash Flow to Firm (Quarterly) | -27.29M |
| Free Cash Flow Yield | -29.11% |